The University of Chicago Header Logo

Connection

Ralph Weichselbaum to Radiosurgery

Back to Details
This is a "connection" page, showing publications Ralph Weichselbaum has written about Radiosurgery.
Ralph Weichselbaum
Connection Strength
4.565
Radiosurgery
  1. Amphiregulin as a Mediator of Radiation-Induced Systemic Effects in Metastatic Cancer: Balancing Local Control with Distant Progression. Clin Cancer Res. 2025 Dec 01; 31(23):4899-4902.
    View in: PubMed
    Score: 0.697
  2. Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal. Eur J Cancer. 2024 04; 201:113972.
    View in: PubMed
    Score: 0.617
  3. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.551
  4. The immunology of ablative radiation. Semin Radiat Oncol. 2015 Jan; 25(1):40-5.
    View in: PubMed
    Score: 0.327
  5. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.306
  6. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013 Apr 10; 31(11):1384-90.
    View in: PubMed
    Score: 0.288
  7. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.262
  8. Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
    View in: PubMed
    Score: 0.169
  9. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
    View in: PubMed
    Score: 0.146
  10. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.130
  11. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.128
  12. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.122
  13. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019 Jan 28; 14(1):18.
    View in: PubMed
    Score: 0.109
  14. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.102
  15. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
    View in: PubMed
    Score: 0.090
  16. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):344-50.
    View in: PubMed
    Score: 0.082
  17. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014 09; 11(9):549-57.
    View in: PubMed
    Score: 0.079
  18. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.076
  19. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013 Jun; 12(3):217-24.
    View in: PubMed
    Score: 0.072
  20. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.071
  21. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008 Sep 01; 98(3):202-6.
    View in: PubMed
    Score: 0.053
  22. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.026
  23. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.023
  24. Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis. J Thorac Oncol. 2015 Feb; 10(2):264-71.
    View in: PubMed
    Score: 0.021
  25. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.